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Introduction
Most cancers acquire six functional capabilities during
their development, including self-sufficiency in growth
signals, insensitivity to growth-inhibitory signals, eva-
sion of programmed cell death (apoptosis), limitless
replicative potential, sustained angiogenesis, and tis-
sue invasion and metastasis [1]. The order in which
these capabilities are acquired seems to be quite vari-
able across the spectrum of cancer types and subtypes.
Importantly, the acquisition of metastatic ability leads
to clinically incurable disease for most cancer cell
types [2]. Cancer metastasis is a critical factor in the
prognosis of cancer patients and is considered to be a
significant contributor to mortality. Improvements in
surgery and radiotherapy and the development of new
chemotherapeutic agents or their use in new combina-
tions have, so far, only incrementally improved patient
survival. Despite the metastatic process remaining
incompletely characterized at the molecular and bio-
chemical levels [3], a novel class of genes—metastasis
suppressors—identify new facets of the process and 
are important therapeutic targets. The first metasta-
sis suppressor, nm23, was identified in 1988 [4], and
since then eight suppressor genes have been confirmed
[2]. These suppressor genes comprise NM23, MKK4,
KA11, BRMS1, KiSS1, RHOGD12, CRSP3, and VDUP1.
Because many studies have correlated the nm23 gene
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with metastasis and prognosis for gynecologic cancers,
it is very important to recognize this gene.
Discovery of Nm23/NDP Kinases
Nucleoside diphosphate (NDP) kinase was first dis-
covered in yeast [5] and in pigeon breast muscle [6].
In human erythrocytes and other mammalian tissues,
electrophoretic profiles were complex, suggesting that
several isozymes were present [7,8]. The first primary
structures for NDP kinases were reported in 1990 for
Myxoccus xanthus [9], Dictyostelium discoideum [10], and
rat [11]. This led to the discovery that the product 
of an independently isolated regulatory gene is NDP
kinase [12]. The first nm23 gene was isolated by Steeg
et al in 1989, on the basis of its reduced expression in
highly metastatic murine meloma cell lines, as com-
pared with their nonmetastatic counterparts, and has
been proposed as a metastatic suppressor gene [4].
They utilized differential colony hybridization to ana-
lyze seven cell lines derived from a murine K-1735
melanoma with varying metastatic potential. They
found that clone 23, exhibiting the highest RNA levels,
was associated with lower metastatic potential. There-
fore, this gene was termed as nonmetastatic clone 23,
which was abbreviated to nm23. The second nm23
gene of mouse was subsequently found by Urano et al
and termed nm23-M2 [13]. Then the gene, which was
found by Steeg et al, was regarded as nm23-M1. In
1989, the first human equivalent was isolated by screen-
ing a human fibroblast cDNA library [14]. Rosengard 
et al identified the nm23 gene, for which RNA levels
were reduced in tumor cells of high metastatic poten-
tial. This gene was referred to as nm23-H1. The human
Nm23 protein has sequence homology over the entire
translated region with a described developmentally regu-
lated protein in Drosophila, encoded by the abnormal
wing discs (awd) gene. Thus far, at least eight genes
(nm23-H1 to nm23-H8) have been documented [15].
Human Nm23/NDP Kinases Family
A second human gene, nm23-H2, was identified by its
high homology to nm23-H1 [16,17]. The nm23-H1
and nm23-H2 gene products share 88% identity.
The protein products of nm23-H1 and nm23-H2 
are identical to human NDP kinase A and NDP kin-
ase B, separately. The nm23-H3 gene (also known as 
DR-nm23) was identified by differential screening of 
a cDNA library obtained from chronic myelogenous
leukemia cells [18]. The remaining five members of the
nm23 gene, named nm23-H4 to nm23-H8, were iden-
tified by searching for homologous sequences in the
expressed sequence tags database [19–22], although,
as far as we know, they do not affect metastatic poten-
tial. Lacombe et al found that eight human genes of
the nm23/NDP kinase family can be separated into
two groups based on the analysis of their sequences
[15]. The group I (Nm23-H1 to -H4) genes encode
proteins, which possess the classic enzymatic activity
of an NDP kinase. This group includes NDP kinases
A–D, which share 58–88% identity with each other.
The protein products of the group II genes (Nm23-H5
to -H8) are more divergent as the sequences share only
25–45% identity with the first group proteins and
between each other.
However, only one product of group II genes
(Nm23-H6) has been demonstrated to catalyze the
NDP kinase reaction.
Functions of Human Nm23/NDP
Kinases
Nucleoside diphosphate kinase activity
The nm23-H1 gene product has been proposed to be
an NDP kinase on the basis of its homology with the
Dictyostelium discoideum enzyme [10,12]. It has been 
further identified as the human NDP kinase A isoform
purified from erthrocytes, whereas the nm23-H2 gene
product has been identified as the NDP kinase B iso-
form [17]. The NDP kinases are 17–20 kDa proteins that
are distributed ubiquitously and catalyze the phospho-
rylation of nucleoside diphosphates to the correspon-
ding nucleoside triphosphates, mainly at the expense of
the ATP synthesized through oxidative phosphorylation
[23]. It can be expressed by a formula: 
The enzymatic activity involves the transfer of the 
-phosphate of nucleoside triphosphate (NTP) to
NDP, where N1 and N2 can be ribo- or deoxyribonucleo-
sides, via a high-energy Nm23-phosphohistidine inter-
mediate [24]. The mechanism also involves a conserved
histidine, namely histidine 118 (amino acid sequence
118: histidine) in the human enzymes [17], as a phos-
phorylated intermediate with a high-energy bond 7
kcal/mole [24,25].
Metabolic roles of mammalian NDP kinases
Until now, the widely accepted roles of NDP kinases
are: (1) to use ATP as a donor to synthesize the non-
adenylic NTPs needed for nucleic acid synthesis and
N1TP  N2DP N1DP  N2TP
NDP kinase
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several important metabolic intermediates including
UDP-glucose and a few CDP-lipid derivatives; (2) to
catalyze transphosphorylation between GTP produced
in the Krebs cycle and ADP; and (3) to provide GTP 
for protein synthesis, G-protein signaling, and tubulin
polymerization [15]. Nonadenylic nucleotides, especially
GTP, play a number of key metabolic and regulatory
roles in the cell. Furthermore, the ratio of [GTP]/[GDP]
and [ATP]/[ADP] can be maintained differently if they
are generated by different metabolic processes and if
NDP kinase is prevented from freely equilibrating the
guanine and adenine nucleotide pools.
Cellular response to nm23-H1
In our laboratory, we found that different cervical cancer
cells exerted different Nm23-H1 protein levels. Excessive
Nm23-H1 protein content were found in HeLa cells
using Western blotting. On the contrary, in Caski cells,
no Nm23-H1 protein was detected. The amount of
Nm23-H1 protein detected in SiHa cells ranged between
that in HeLa and Caski cells. Using matrix zymography
(it is applied to detect the function of matrix metallopro-
teinase), Caski cells (no Nm23-H1 protein content) were
found to exhibit the highest proteinase function, which is
related to degradation of extracelluar matrix and then
invasion. In contrast, HeLa cells (excessive Nm23-H1
protein content) present little proteinase function.
Therefore, in cellular levels, nm23-H1 seems to inhibit
the metastatic potential of cervical cancer cells. The
interesting cellular response is also demonstrated in dif-
ferent cancer cell types. In melanoma and breast carci-
noma cells overexpressing nm23-H1, a reduced response
to the cytokine TFG-1 was found [26,27]. Further-
more, Kantor et al also found that their motility in res-
ponse to serum and platelet derived growth factor is
markedly inhibited [28]. In addition, medroxyproges-
terone acetate appears to elevate Nm23-H1 metastasis
suppressor gene expression, thereby reducing metasta-
tic colonization in metastatic human breast carcinoma
cells [29,30].
In the L9981 lung cancer cell line, the nm23-H1
gene can reverse the malignant and metastatic pheno-
type of cancer cells through regulating the expression 
of lung cancer metastasis-related genes [31,32]. In the
DU 145 prostate cancer cell line, the nm23-H1 gene
product suppresses metastatic potential by inhibiting
ability of cancer cells in anchorage-independent growth
and extracellular matrix adhesion [33].
Although histidine 118 (amino acid sequence 118:
histidine) is involved in Nm23’s NDP kinase activity,
MacDonald et al found that mainly serine 120 (amino
acid sequence 120: serine), instead of histidine 118, may
be contributory to its tumor metastasis-suppressive
capacity [34]. They utilized site-directed mutagenesis for
proline 96 or serine 120 of nm23-H1 in MDA-MB-435
human breast carcinoma cells to abrogate its motility
inhibitory activity in breast cancer cells. MacDonald
et al also showed that Nm23 serine phosphorylation
cannot directly participate in the NDP kinase activity 
of Nm23 because of its low bond energy. Lee and Lee
further indicated that alterations at the histidine 118
residue, which result in loss of NDP kinase activity of
nm23-H1, do not affect nm23-H1’s inhibitory activity
on the colonogenicity of DU 145 prostate carcinoma
cells [35]. They suggested that the metastasis sup-
pressing function of nm23-H1 is independent of the
NDP kinase enzymatic activity. Freije et al found that
the Nm23-H1 (S120A) mutant (amino acid sequence
120: serine is mutated to alanine) was deficient in only
histidine-dependent serine autophosphorylation [36].
Nm23-H1 and Nm23-H1 (S44A) mutant (amino acid
sequence 44: serine is mutated to alanine) exhibited nor-
mal activity in all assays conducted. Based on this corre-
lation, they hypothesized that a histidine-dependent
protein phosphotransfer activity of Nm23-H1 may 
be responsible for the biological suppressive effects of
nm23-H1.
The metastasis suppressive function of nm23 was pre-
viously correlated with its histidine protein-kinase activity
in a site-directed mutagenesis experiment [36]. Further-
more, Nm23 is reported to co-immunoprecipitate the
kinase suppressor of Ras (KSR) protein—a scaffold
protein for the ERK-MAPK (extracellular signal-regulated
kinase mitogen-activated protein kinase) pathway and
phosphorylate KSR serine; further alter its scaffold
function and could lead to reduced ERK activation in
response to signaling [37–45].
In contrast, Valentijn et al found that N-myc upreg-
ulates expression of nm23-H1 gene in neuroblastoma
cells and increases Nm23-H1 protein levels. Thereafter,
Nm23-H1 protein binds to cell division cell 42 and pre-
vents the induction of differentiation [46]. This may
increase the metastatic potential of neuroblastoma cells.
In brief, nm23 may play a tissue-specific role, and
influence the metastatic behavior of different cancer cells
via different regulatory mechanisms. An inverse relation-
ship, however, exists between Nm23-H1 protein and
metastatic potential in most cancer cell types except in
rare cancer cell types (such as neuroblastoma cells).
Interestingly, Nm23/NDP kinase is further demon-
strated to link cytoskeletal components, tubulin and
vimentin, which are involved in the spatial features of
cell signaling [47–50]. Activation of transmembrane
receptors often affects cytoskeletal organization and
the association of Nm23/NDP kinase with structural
proteins, such as vimentin, could affect the dynamics
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of cytoskeleton remodeling following external stimu-
lation. Vimentin networks show a tendency to form
tangles and bundles and can be more densely packed
when assembled in the presence of Nm23/NDP
kinase, presumably because more than one filament
can interact with the Nm23/NDP kinase hexamer.
Overexpression of Nm23/NDP kinase could reduce the
flexibility necessary for cytoskeleton plasticity and cell
movement and this property could be the basis for the
motility suppressive actions [51,52]. Thereafter, tissue
invasion of cancer cells is inhibited.
Nm23-H1 Expression in Various 
Tumors
Nm23-H1 has been regarded as metastasis-associated
genes in various tumors [15,53]. Reductions in nm23
expression have been significantly associated with aggres-
sive behavior in melanoma, gastric, colon, and breast
carcinoma. Expression of nm23-H1 is inversely propor-
tional to the metastasis of these carcinomas [54–57].
On the contrary, high levels of nm23 gene expression 
are noted in the advanced stage of thyroid carcinomas
[58,59]. In addition, elevated nm23-H1 expression is
associated with a significant reduction in survival for
neuroblastoma and osteosarcoma patients [60,61].
However, Szumilo et al suggest that nm23 status is 
not associated with metastatic ability and prognosis 
in esophageal squamous cell carcinoma (SCC) [62].
Obviously, nm23 may play a tissue-specific role, and
different regulatory mechanisms may act in different
tumors.
Nm23-H1 Expression in Gynecologic
Tumors
Nm23-H1 and ovarian cancer
Mandai et al demonstrated that low levels of nm23-H1
expression have been associated with lymph node
metastasis and advanced stage in ovarian carcinoma
[63]. Tas et al found that the nm23 staining was more
intensive in patients with normal serum CA19.9 levels,
patients with nonrecurrent disease, and alive patients
(p < 0.05). However, they found that Nm23 expression
was not correlated with common clinicopathologic
parameters such as histology, grade of differentiation,
International Federation of Gynecology and Obstetrics
stage, and CA-125 [64]. They also demonstrated that
nm23 may have a favorable prognostic impact on ovar-
ian cancer. In contrast, Tomic et al reported that the
overexpression of nm23 proteins was associated with
advanced clinical stage, high grade, and/or presence of
vascular invasion for epithelial ovarian carcinoma [65].
They found that this overexpression, however, had no
independent prognostic value either for overall survival
or survival corrected by clinical stages. Therefore, the role
of nm23-H1 in ovarian carcinoma remains unclear.
Nm23-H1 and cervical cancer and dysplasia
Marone et al demonstrated that cervical cancer
patients with lymph node involvement have signifi-
cantly lower protein levels of nm23-H1 [66]. But they
did not mention the histologic type of cervical cancer.
Moreover, negative expression of nm23-H1 in cervical
cancer has been found to be associated with a high
incidence of lymph node metastasis in adenocarci-
noma, but not in SCC [67]. However, Kristensen et al
did not find immunostaining for nm23 to be a useful
prognostic indicator in cancer of the uterine cervix [68].
Our previous study correlated nm23-H1 immunore-
activity with clinicopathologic variables; a trend was
determined for high nm23-H1 expression for older
women and metastatic status, however, statistical 
significance was not achieved. Further, a significant
relationship with high nm23 expression was only
demonstrated for deep stromal invasion (1/2 stro-
mal invasion depth) [69]. In addition to parametrial
involvement, grade and lymph node metastasis, Sarac
et al also did not find a significant association between
nm23 expression and deep stromal invasion [70]. They
did not, however, define the depth of stromal invasion.
It seems reasonable to suggest that the relationship
between deep stromal invasion and high nm23 expres-
sion is attributable to nm23/NDP kinase-related cellular
proliferation. Furthermore, we also found that high
cumulative recurrence hazard was demonstrated in the
high nm23 expression subgroup of cervical cancer [69].
Our findings were in accordance with those of Chen 
et al, who found a significant association between lower
recurrence-free survival rate (higher recurrence) and
nm23 overexpression [71].
Many investigators have correlated nm23-H1 expres-
sion with metastatic potential, but few have studied its
role in tumor progression. In another study, we found sig-
nificant differences in the levels of nm23-H1 expression
between low-grade squamous intraepithelial lesion
(LSIL) and high-grade squamous intraepithelial lesion
(HSIL) and between LSIL and SCC, but not between
HSIL and SCC or normal and LSIL samples [72].
Furthermore, a positive relationship was demonstrated
for high nm23-H1 protein expression and degree of
malignant transformation. High nm23-H1 expression
appears to be related to critical progression of LSIL to
HSIL in cervical carcinogenesis. These findings are
consistent with the findings of Ravazoula et al, who
demonstrated general trends of increasing immuno-
reactivity of nm23-H1 protein and progressively greater
atypia in cervical epithelium [73]. Our findings are fur-
ther supported by Weber et al and Ohneda et al [74,75].
Weber et al showed that Nm23/NPD kinases are cru-
cial for the supplement of nucleoside triphosphates
required for nucleic acid synthesis. Thus, an increased
expression of this enzyme is linked to cellular prolifera-
tion. Ohneda et al suggested that cell transformation
and immortalization in the early stage of tumorigenesis
could induce nm23 gene overexpression, resulting in
increased expression of nm23 gene product. Therefore,
the nm23-H1 gene is not only involved in cervical car-
cinogenesis but also plays a critical role.
Conclusively, a high level of expression of the nm23-
H1 gene product is found in most HSIL and SCC cases.
High expression of Nm23-H1 protein indicates a critical
progression from LSIL to HSIL involved in the subse-
quent emergence of invasive SCC. Ascending degree of
malignant transformation of cervical squamous neo-
plasia is reflected in the trend of increasing levels of 
nm23-H1 gene product expression. Because some
conflicting findings still exist between the expression of
nm23/NDP kinase and clinicopathologic characteris-
tics in many studies of cervical cancer, we still cannot
draw a conclusion concerning nm23-H1 with metasta-
sis. However, overexpression of Nm23-H1 protein seems
to predict a poor survival for cervical cancer patients.
Conclusion
Nm23-H1/NDP kinase is associated with tumor metas-
tasis. Although its expression is divergent in various
malignant tumors, its reduced expression seems to be
related to increased metastatic potential in most can-
cer cell types. In ovarian carcinoma, the relationships of
nm23-H1/NDP kinase and clinicopathologic charac-
teristics still remain to be clarified. In cervical cancer, in
addition to patients’ survival, nm23-H1 may also be
involved in cervical carcinogenesis. Recent studies show-
ing that Nm23 co-immunoprecipitates the KSR pro-
tein and, therefore, reduces ERK-MARK activation in
response to signaling are interesting and warrant 
further research.
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